Swiss National Bank Sells 174,800 Shares of CVS Health Corporation $CVS

Key Points

• Swiss National Bank trimmed its CVS stake by 4.6%, selling 174,800 shares in Q3 and now holds 3,646,560 shares valued at about $274.9 million (roughly 0.29% of the company).
• Institutional ownership stands at 80.66%, with large moves including Norges Bank’s new ~$1.36 billion position and sizable stake increases from Invesco and Vanguard.
• CVS recently beat quarterly estimates (EPS $1.09 vs. $1.00; revenue $105.69B vs. $103.67B), set FY2026 EPS guidance of 5.94–6.14, and pays a $0.665 quarterly dividend (3.4% yield) with a 192.75% payout ratio.

Swiss National Bank reduced its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 4.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,646,560 shares of the pharmacy operator's stock after selling 174,800 shares during the period. Swiss National Bank owned 0.29% of CVS Health worth $274,914,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in CVS. Norges Bank acquired a new stake in CVS Health in the 2nd quarter worth approximately $1,358,698,000. Invesco Ltd. lifted its stake in shares of CVS Health by 15.3% in the second quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator's stock worth $1,623,270,000 after buying an additional 3,118,626 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of CVS Health by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator's stock worth $8,305,132,000 after buying an additional 2,063,737 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in CVS Health by 153.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,105,827 shares of the pharmacy operator's stock valued at $214,240,000 after buying an additional 1,878,217 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its holdings in CVS Health by 2,675.7% in the 2nd quarter. Panagora Asset Management Inc. now owns 1,116,742 shares of the pharmacy operator's stock worth $77,033,000 after acquiring an additional 1,076,509 shares during the period. Institutional investors own 80.66% of the company's stock.

CVS Health Trading Down 1.0%

Shares of CVS opened at $77.91 on Monday. The stock's 50-day moving average price is $78.49 and its 200 day moving average price is $77.65. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $99.12 billion, a price-to-earnings ratio of 56.46, a P/E/G ratio of 0.81 and a beta of 0.49. CVS Health Corporation has a 12-month low of $58.35 and a 12-month high of $85.15.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.09. The company had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.CVS Health's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. As a group, research analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend was Thursday, January 22nd. CVS Health's payout ratio is 192.75%.

Wall Street Analyst Weigh In

CVS has been the subject of a number of recent analyst reports. UBS Group restated an "outperform" rating on shares of CVS Health in a report on Wednesday, December 10th. Leerink Partners reiterated an "outperform" rating and issued a $98.00 price objective on shares of CVS Health in a research note on Thursday. JPMorgan Chase & Co. increased their target price on CVS Health from $93.00 to $101.00 and gave the company an "overweight" rating in a research note on Wednesday, December 17th. Mizuho upped their price target on CVS Health from $88.00 to $95.00 and gave the stock an "outperform" rating in a report on Wednesday, December 10th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating on shares of CVS Health in a research report on Thursday, December 4th. Nineteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $94.91.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.